Medtronic acquires neurovascular access device maker Scientia Vascular for $550M

Medtronic plc has completed its acquisition of Scientia Vascular, a Salt Lake City-based medical device company focused on neurovascular access technologies, the Dublin-headquartered health technology company announced.

The deal is valued at $550 million, subject to customary adjustments, with additional earn-out and milestone payments possible. Financial terms of those contingent payments were not disclosed.

Scientia, which employs roughly 310 people, specializes in guidewires and catheters designed to help physicians navigate the brain's complex vascular anatomy to treat conditions such as stroke and aneurysms. The company's products are intended to integrate with Medtronic's existing neurovascular portfolio, which includes liquid embolic agents, stent retrievers and flow diverters.

Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, said combining the two companies' technologies would help physicians treat patients more efficiently.

"By bringing together highly complementary technologies, we are building a more integrated platform that will help advance the future of neurovascular care," Burman said in a statement.

Stroke is the third leading cause of death and the leading cause of disability worldwide, according to the company. Cerebral vasculature is notably more tortuous than vessels elsewhere in the body, complicating physicians' efforts to reach the site of a blockage or aneurysm quickly. Scientia's platform is designed to improve navigability through that complex anatomy.

Rick Randall, Scientia's CEO, said joining Medtronic would expand the reach of the company's technology globally.

Medtronic said the acquisition is expected to be minimally dilutive to its adjusted earnings per share in fiscal year 2027 and accretive thereafter.

Scientia was founded by John Lippert, who remains with the company as chief technology officer.